Shishodia G, et al. - Researchers exhibited for the first time, that protocadherin (PCDH)7 is overexpressed in a large number of patients with castrate-resistant prostate cancer (CRPC). PCDH7 expression was investigated in CRPC/neuroendocrine prostate cancer (NEPC) dataset. In 41% of patients, in CRPC/NEPC dataset, PCDH7 amplification/mRNA upregulation was noted. In CRPC cells, PCDH7 was also overexpressed. During tumor progression in PCa tissues and in TRAMP mice, increased PCDH protein expression was perceived. Epidermal growth factor treatment led to aberrant activation of ERK/AKT. The knockdown of PCDH7 reduced ERK, AKT, and RB phosphorylation and decreased colony formation, diminished cell invasion, and cell migration. These data reveal that in a large number of patients with CRPC, PCDH7 is overexpressed and infer that in subsets of patients with CRPC for whom there is no cure to-date, PCDH7 may be an attractive target.